Lippo China Resources Limited Overview
Lippo China Resources is a Hong Kong-listed, Riady-family-controlled investment holding company. In practice it is a small Asian consumer-food operator wrapped around a portfolio of property, listed and unlisted securities, and two significant Singapore associates. Food businesses generate about 95% of consolidated revenue (HK$821m of HK$864m in FY2025). They comprise industrial bread manufacturing in Singapore and Malaysia and a café/restaurant estate in Hong Kong and Singapore operating under the Délifrance, Chatterbox Café, alfafa and Lippo Chiuchow names. Below the operating line, earnings are dominated by fair-value marks on a ~HK$0.5bn securities book, revaluation of Hong Kong commercial property, and equity-accounted results from Healthway Medical (40.76%; 130+ Singapore clinics) and SGX-listed TIH Limited (39.92%; private equity and fund management). The shares trade at roughly 0.45–0.5x book. After the 2024 Skye litigation settlement and the 2026 insurance recovery, the investment case rests on food-manufacturing growth in Malaysia, NAV realisation, and the governance direction of the Riady group.
Company's own description (latest annual results, FY2025)
In its FY2025 results announcement, the company defines seven reportable segments [S1]:
-
Property investment: investments in letting and resale of properties.
-
Treasury investment: money-market investments.
-
Securities investment: securities held for trading and for long-term strategic purposes.
-
Food businesses: mainly food manufacturing, plus food retail through café and bistro chains.
-
Healthcare services: healthcare management services.
-
Property management: property management services.
-
Other: principally property development and sale, mineral exploration and extraction, and investment in a closed-end fund.
Management describes food businesses as the principal source of revenue, contributing 95% of FY2025 revenue (FY2024: 94%) [S1]. The food manufacturing operation sells various bread products in Singapore and Malaysia. The restaurant operation runs "Chatterbox Café", "Délifrance", "alfafa" and "Lippo Chiuchow Restaurant" in Hong Kong and "Délifrance" in Singapore [S1].
Revenue model
| Revenue type (FY2025) | HKD Mn | % of total | Nature |
|---|---|---|---|
| Food manufacturing (bread, Singapore & Malaysia) | 436.6 | 50.5% | Product sales, B2B/B2C via retail channels; recognised at a point in time |
| Restaurant operation (HK & Singapore) | 382.7 | 44.3% | Consumer F&B sales; recognised at a point in time |
| Management services (mainly property management) | 12.6 | 1.5% | Service fees; recognised over time |
| Property rental income | 17.4 | 2.0% | Operating-lease rentals |
| Dividend income | 10.0 | 1.2% | Investment income |
| Interest income | 2.4 | 0.3% | Investment income |
| Other | 2.8 | 0.3% | Miscellaneous |
| Total | 864.5 | 100% | — |
Source: FY2025 Final Results, Note 4 [S1].
Mix characterisation. About 95% of revenue comes from products (bread and F&B), about 3.5% from services and rental, and about 1.5% from investment income. There is no subscription or licensing revenue. Revenue understates the economic importance of the investment portfolio. Fair-value movements, revaluation, impairments and equity-accounted results sit outside revenue and have historically driven the bottom line. In FY2024, for example, a HK$386.5m litigation settlement and a HK$63.3m fair-value loss outweighed a HK$474.6m gross profit [S1].
Value-chain position, customers and end-markets
Food manufacturing: LCR is a mid-stream manufacturer. It buys flour and other inputs, operates baking lines and distributes packaged bread through retail and food-service channels in Singapore and, increasingly, Malaysia. Customer concentration is material: a single food-segment customer contributed HK$130.7m in FY2025 (15.1% of group revenue), up from HK$119.8m in FY2024, HK$114.7m in FY2023, HK$91.8m in FY2022 and HK$96.5m in FY2021 [S1][S2][S3]. The customer's identity is not publicly disclosed; it is most plausibly a large grocery retailer or distributor.
Food retail: LCR is downstream, consumer-facing, and exposed to Hong Kong discretionary spending, cross-border ("northbound") leakage, rent and labour costs.
Property: LCR is a small landlord of Hong Kong and Mainland commercial property, with rental income of HK$17.4m in FY2025 [S1].
Investments: LCR acts as a capital allocator, holding listed and unlisted equities, funds and debt. Its two principal associates are Healthway Medical (Singapore primary and specialist healthcare) and TIH Limited (Southeast Asian private equity and fund management) [S1].
End-markets: Singapore (54% of FY2025 revenue), Hong Kong (32%), Malaysia (12%), Mainland China (<1%) and other (1%) [S1].
Independent characterisation
LCR is best described as a holding-company discount vehicle whose consolidated P&L is a bakery-and-café business attached to a sizeable but non-core investment balance sheet. On a sum-of-the-parts view at 30 June 2026, associates (HK$912.7m), the FVPL portfolio (HK$492.3m), FVOCI equities (HK$31.2m), joint ventures (HK$41.8m) and investment properties (HK$580.8m) total about HK$2.06bn of carrying value [S4]. That is more than double the ~HK$0.94bn market capitalisation, before counting the food operations' fixed assets (HK$789.6m), and against borrowings of HK$916m [S4]. The operating engine is improving (analyst-derived adjusted EBITDA rose from HK$19m in FY2023 to HK$82m in FY2025). However, the business has not generated sustainable profit since FY2021 apart from one-offs. The discount reflects controlled-company governance, low free float (~17–27% depending on how the Tai holding is treated), illiquidity, and a record of value-destructive events such as the Skye/CS Mining litigation.
Strategy
Stated strategic themes (latest annual and interim reports)
LCR does not publish a formal multi-year strategy, investor-day material or numeric targets. Recurring management themes in the FY2023–H1 2026 filings are paraphrased below:
-
Prudent capital management and cautious asset monitoring. Repeated in every prospects section: the group and its associates will manage businesses cautiously, monitor assets and investments, and manage capital prudently [S1][S2][S4].
-
Innovation and reinvestment in food offerings. Management says it monitors market changes and innovates and reinvests in its products to meet customer preferences [S1][S4].
-
Production capacity and efficiency. The Dec 2025 equipment purchase was described as value-adding to the existing business [S1].
-
Malaysia expansion of food manufacturing, cited as a key revenue driver [S1][S4].
-
Proactive but prudent portfolio management. Investments are run under an investment committee's terms of reference, seeking yield enhancement. Gains are realised (for example, Quantedge redemptions) to fund working capital [S1][S4].
-
Balance-sheet repair for future distributions. The 2025 Capital Reduction was explicitly aimed at greater flexibility for corporate exercises and dividends [S1][S22].
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Target / status | Source |
|---|---|---|---|---|
| Litigation exit and insurance recovery | Sep 2024 – Feb 2026 | Settled Skye/CS Mining litigation for US$49.5m; recovered US$24.75m from corporate-liability insurers | Complete | [S1][S4] |
| Capital Reduction | Effective 29 Jul 2025 | Share capital cut to HK$150m; HK$0.7bn offset against accumulated losses (accumulated losses were ~HK$636m at company level before the reduction) | Complete | [S1][S22] |
| Group restructuring – Lippo Limited privatisation | May–Sep 2025 | Parent privatised; LCR shares distributed to Lippo shareholders (cash alternative HK$0.564 per Lippo share) | Complete 23 Sep 2025 | [S12] |
| Food manufacturing capacity | Dec 2025 – Q4 2026 | New commercial bread line; capital commitments HK$153–160m | Installation expected Q4 2026 | [S1][S4] |
| Malaysia market expansion | 2024–2026 | Malaysia food revenue up from HK$31.4m (FY2024) to HK$105.2m (FY2025) | Ongoing | [S1] |
| Restaurant estate rationalisation | H1 2026 | Store closures in Hong Kong | Ongoing | [S4] |
| H2G Green stake build | 2025–2026 | Warrants exercised (+HK$13m), stake rose to 28.8%; board-nomination right obtained, making H2G an associate; diluted to 22.5% by placement | Ongoing | [S1][S4] |
| Investment portfolio de-risking | 2022–2026 | Treasury and securities portfolio reduced from HK$1,947m (FY2021) to HK$731m (FY2025) | Ongoing | [S1][S3] |
ESG commitments, cost programmes and medium-term guidance
Sustainability commitments: No quantified targets were found in retrieved sources.
Cost programmes: No formal programme with targets is disclosed. Legal and professional fees fell from HK$56.5m (FY2024) to HK$6.4m (FY2025) after the settlement [S1].
Medium-term financial targets or guidance: Not publicly disclosed. Management provides only qualitative macro outlooks, noting upward revisions to Hong Kong 2026 GDP forecasts (3.5–4.5%) and Singapore (4.5–5.5%) while flagging Middle East geopolitical risk [S4].
Products & Services
Food businesses — Food manufacturing
| Offering | Description | Market / target customer | Launch / status | Pricing model | Source |
|---|---|---|---|---|---|
| Packaged bread products (Singapore) | Industrial production of various bread products sold through retail and food-service channels | Singapore mass grocery consumers and institutional buyers; one customer = HK$130.7m in FY2025 | Long-established; continued growth in FY2025 | Wholesale/retail list pricing (not disclosed) | [S1] |
| Packaged bread products (Malaysia) | Expansion of the bread range into Malaysia; Malaysian share of food-manufacturing revenue rose from 9% (FY2024) to 24% (FY2025) | Malaysian grocery channel | Expansion accelerated 2024–2026 | — | [S1] |
| New products (unspecified) | Management cites "launch of new products" as a growth driver in FY2025 and H1 2026 | Singapore and Malaysia | 2025–2026 | — | [S1][S4] |
| Historical brand portfolio (context) | Auric's 2015 annual report shows Sunshine and Top One breads made at Auric's own facilities, the Buttercup spread, Sunshine frozen pizza and Gourmet delicatessen brands, plus a Malaysian unit, Auric Pacific Food Processing Sdn. Bhd. | Singapore and Malaysia | Historical (2015) | — | [S14] |
| New commercial production line | One line of commercial food-manufacturing equipment agreed in Dec 2025; installation expected in Q4 2026 | Capacity and efficiency | Commissioning Q4 2026 | Capex (part of HK$153–160m commitments) | [S1][S4] |
Food businesses — Food retail (restaurants and cafés)
| Brand | Format | Geography | Notes | Source |
|---|---|---|---|---|
| Délifrance | French-style café-bakery and bistro | Hong Kong and Singapore | Owned via Délifrance Asia (acquired 2007). Rebranding with "Délifrance Bistro" concept launched in Hong Kong in March 2023 | [S1][S2][S3][S14] |
| Chatterbox Café | Casual dining (Singapore-style cuisine) | Hong Kong | Two new outlets opened in 2023 | [S1][S2] |
| Chatterbox Express | Express format | Hong Kong | Listed in FY2022–FY2023 filings; not listed among FY2025 or H1 2026 brands, implying discontinuation or rebranding (not explicitly disclosed) | [S2][S3][S1] |
| alfafa | Café/casual dining | Hong Kong | Ongoing | [S1] |
| Lippo Chiuchow Restaurant (力寶軒) | Chiu Chow (Teochew) Chinese restaurant | Hong Kong | Ongoing | [S1][S4] |
Outlet counts, average ticket, same-store sales and menu pricing are not publicly disclosed. H1 2026 disclosures note that "some stores were closed" in Hong Kong [S4].
Property investment and property management
| Offering | Description | Source |
|---|---|---|
| Commercial investment properties | Portfolio mainly of commercial properties in Hong Kong and Mainland China; carrying value HK$566.9m (Dec 2025), HK$580.8m (Jun 2026). Individual property names and GFA not disclosed in the retrieved filings | [S1][S4] |
| Owner-occupied office buildings | Fixed assets including HQ-type offices in Hong Kong; impaired HK$79.9m (FY2024) and HK$40.5m (FY2025) | [S1] |
| Property management services | Fee-based services in Hong Kong (HK$10.3m) and Mainland China (HK$2.0m) in FY2025 | [S1] |
Treasury and securities investments (principal positions)
| Holding | Type | Carrying value (latest) | Description | Source |
|---|---|---|---|---|
| GSH Corporation Limited | Listed equity (SGX Mainboard), FVPL | HK$80.1m (Jun 2026); HK$83.3m (Dec 2025) | Malaysian and Mainland property and hospitality: Sutera Harbour Resort in Kota Kinabalu (two five-star hotels, 104-berth marina, 27-hole golf course), Sutera@Mantanani Resort, and a 200-room Chongqing hotel. Placed ~S$112m of new shares in 2025 and earmarked ~S$35m for digital-asset mining | [S1][S4] |
| Amasia CIV T, L.P. | Unlisted single-asset fund, FVPL | HK$56.4m (Jun 2026) | Holds Dialpad, Inc. (AI-powered communications and contact-centre platform). US$2m invested in 2015 | [S1][S4] |
| Quantedge Global Fund | Unlisted multi-asset fund, FVPL | HK$50.1m (Jun 2026) | Partial redemptions used for working capital (HK$9m in FY2025, HK$3m in H1 2026) | [S1][S4] |
| Other FVPL securities | Equities, debt, funds | HK$305.7m (Jun 2026) | No single item above 7% of FVPL | [S4] |
| GenieBiome Holdings | Unlisted biotech, FVOCI | HK$23m (Jun 2026) | Hong Kong microbiome precision-health company founded by university clinician-scientists; pays dividends | [S1][S4] |
| H2G Green Limited | SGX Catalist; associate from H1 2026 | HK$33m (Jun 2026); ~22.5% stake | LNG cylinder supply for last-mile clean-energy distribution. Sold its biomass-to-fuel subsidiary in July 2026 to focus on LNG | [S1][S4] |
Healthcare services (associate)
| Offering | Description | Source |
|---|---|---|
| Healthway Medical Group (40.76%) | Network of 130+ clinics, primarily in Singapore: GP and family medicine, health screening, adult specialists, baby and child specialists, dental, a day-surgery centre and allied health. Participant in the national Healthier SG programme (65 clinics enrolled as of FY2023). Brands and acquisitions include Nobel specialist clinics, Straits Podiatry, Ten Surgery Group, Amazing Speech Therapy, HeadStart for Life, TeleHope Speech Therapy and UROHEALTH (urology). In July 2026, proposed acquisition of the Bridgepoint Health network of 16 primary-care clinics | [S1][S2][S3][S4] |
Other
| Offering | Description | Source |
|---|---|---|
| TIH Limited (39.92%) | SGX-listed investment business (special situations, secondary portfolios, private credit, long-term private equity) and fund management via TIH Investment Management Pte. Ltd., which holds an MAS capital markets services licence | [S1][S3] |
| Mineral exploration and extraction | Residual activity within "Other". Capital expenditure definitions include exploration and evaluation assets; specific projects not disclosed | [S1] |
| Closed-end fund investment | Within "Other"; fund identity not disclosed | [S1] |
| Property development and sale | Within "Other"; no active projects disclosed | [S1] |
Financial Narrative
Sources: FY2022 Final Results (FY2021–22) [S3]; FY2023 Final Results [S2]; FY2025 Final Results (FY2024–25) [S1]. Currency HK$ million unless stated. FY2025 figures come from the preliminary announcement agreed by EY. The H1 2026 interim confirms the FY2025 statements were subsequently audited with an unqualified opinion [S4].
Income statement
Note: Adjusted EBITDA is post-HKFRS 16 (it adds back right-of-use depreciation). It excludes fair-value, impairment, litigation and associate items. FY2024 other operating expenses include HK$56.5m of legal and professional fees linked to the litigation [S1].
Margins and growth
Revenue CAGR (analyst-derived): FY2021–FY2025 4-year CAGR ≈ 7.4%; FY2022–FY2025 3-year CAGR ≈ 12.5%.
Gross margin is structurally high for a food business because, under LCR's presentation, cost of sales captures mainly cost of inventories sold (HK$330.7m in FY2025). Restaurant labour, rent (via right-of-use depreciation) and utilities sit in administrative and other operating expenses [S1]. For that reason the gross margin should not be compared directly with HK fast-food peers, which report gross margins of 8–10% after including staff and rent in cost of sales.
Per-share data (restated for the 10:1 consolidation of June 2023)
FY2021 EPS was reported as HK0.53 cents pre-consolidation; FY2021 final dividend HK0.45 cents and FY2022 interim HK0.35 cents pre-consolidation [S3]. Diluted EPS equals basic; there are no dilutive instruments [S1].
Balance sheet
Sources: [S1][S2][S3]. Within borrowings, bank loans were HK$765m and unsecured loans from holding companies HK$187m at Dec 2025 (Dec 2024: HK$796m and HK$170m) [S1].
Interim balance sheet (30 June 2026) [S4]: total assets HK$3,483.4m; total liabilities HK$1,242.7m; cash HK$249.4m plus HK$13.5m restricted; borrowings HK$916.1m (current HK$137.5m, non-current HK$778.5m; bank loans HK$784m, related-party loans HK$132m); equity attributable HK$2,015.5m; NCI HK$225.2m; gearing ratio 42.1%; current ratio 1.5.
Cash flow and capital deployment
The FY2024 litigation payment of US$49.5m (HK$386.5m) was a major cash outflow, funded partly by higher borrowings: total borrowings rose from HK$644.8m to HK$965.9m and related-party loans of HK$170m appeared [S1][S2]. The FY2025 HK$77.1m insurance advance and the 2026 balance of HK$115.6m reverse about half of that outflow [S4]. LCR made no repurchases in FY2022–FY2025 or H1 2026 [S1][S2][S3][S4].
Ratios
All ratios are analyst-derived from reported balances [S1][S2][S3]. The company-defined gearing ratio is borrowings net of NCI divided by attributable equity, as reported. Working-capital days use trade debtors and creditors from the ageing notes against total revenue and cost of inventories sold. Net debt/EBITDA is not meaningful (blank) where adjusted EBITDA was negative.
Half-year comparison: notes and sources
Sources: H1 2025 Interim Results (H1 2024–25) [S6]; H1 2026 Interim Results [S4].
Trend commentary
Revenue. Revenue fell in FY2022 (-6.3%) as Hong Kong dine-in restrictions and Malaysian start-up problems hit food sales [S3]. It rebounded in FY2023 (+21.7%) when Hong Kong reopened [S2], grew modestly in FY2024 (+4.9%) and accelerated in FY2025 (+11.5%) on manufacturing [S1]. The growth mix has shifted decisively. Restaurants grew only 2% in FY2025 and fell 13% in H1 2026, while manufacturing grew 25% and then 21% [S1][S4]. Malaysia went from HK$1.0m of revenue in FY2021 to HK$106.8m in FY2025 [S1][S3].
Profitability. Gross margin widened by about 10 points from FY2021 to FY2025, consistent with mix shift and input-cost management. Operating losses narrowed from HK$198m to HK$44m. Even so, administrative costs (HK$436.6m) still consumed 82% of gross profit in FY2025. Staff costs rose 12% in FY2025 to HK$334m with headcount up 7% [S1]. Adjusted EBITDA inflected positive in FY2023 and reached HK$82m in FY2025. H1 2026 adjusted EBITDA of about HK$30m (analyst-derived) was roughly flat on H1 2025.
Below-the-line volatility. FVPL marks swung from +HK$226m (FY2021) to -HK$104m (FY2022). The portfolio was then deliberately shrunk: FVPL assets fell from HK$1,129m to HK$490m. Hong Kong commercial property has been a persistent drag, with cumulative FY2021–FY2025 fair-value losses of HK$112.7m plus HK$120.4m of office impairments. The FY2024 loss of HK$683.7m was dominated by the HK$386.5m litigation settlement. The FY2025 headline loss of HK$61.3m was flattered by a HK$104.2m reversal of prior-year tax over-provision, which collapsed tax payable from HK$119.2m to HK$20.6m [S1]. Without it, the FY2025 pre-tax loss was HK$153.5m.
Balance sheet. Attributable equity fell 39% from HK$3,078m (FY2021) to HK$1,865m (FY2025). Net debt rose from HK$205m to HK$718m while cash fell from HK$860m (including time deposits) to HK$240m. The group is now structurally dependent on secured bank financing plus HK$132–187m of unsecured loans from controlling-shareholder entities [S1][S4]. Refinancing in 2023 cut current-maturity exposure from 64% to 22% of borrowings [S2]. Short-term maturities were 13% at Dec 2025 and 15% at Jun 2026 [S1][S4]. H1 2026 profit and the insurance cash cut gearing to 42.1% from 48.1% [S4].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Level | Entity | Interest | Notes |
|---|---|---|---|
Ultimate controller | Dr. Stephen Riady and family | — | Via Lippo Capital group [S11][S13] |
Shareholder | Skyscraper Realty Limited (subsidiary of Lippo Limited, privatised Sept 2025) | 48.45% of LCR | [S12] |
Shareholder | Lippo Capital Limited | 24.76% of LCR | [S12] |
Shareholder | Mr. Stephen Tai Tak Fung | 9.30% of LCR (as at 31 Mar 2026) | [S11] |
Subsidiary group | Auric Pacific Group and subsidiaries (food manufacturing, Délifrance Asia) | — | NCI of HK$231m at Dec 2025 indicates partly-owned subsidiaries [S1][S14] |
Associate | Healthway Medical Corporation Limited | 40.76% | Healthcare services segment [S1] |
Associate | TIH Limited (SGX Mainboard) | 39.92% | "Other" segment [S1] |
Associate (from H1 2026) | H2G Green Limited (SGX Catalist) | ~22.5% | Reclassified from FVOCI after LCR obtained a board-nomination right [S4] |
Joint venture | Unnamed JV in securities investment segment | — | Impaired by HK$40.7m in FY2025 [S1] |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Property investment external revenue (HKD Mn) | 18.5 | 17.2 | 18.7 | 17.0 | 17.4 |
Treasury investment external revenue (HKD Mn) | 2.4 | 3.6 | 5.9 | 2.8 | 0.5 |
Securities investment external revenue (HKD Mn) | 16.8 | 11.6 | 11.8 | 11.3 | 11.7 |
Food businesses external revenue (HKD Mn) | 596.5 | 560.3 | 687.3 | 727.8 | 821.2 |
Healthcare services external revenue (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Property management external revenue (HKD Mn) | — | 12.9 | 12.5 | 12.5 | 12.3 |
Other external revenue (HKD Mn; FY2021 includes property management) | 14.4 | 1.9 | 3.3 | 3.9 | 1.4 |
Total revenue (HKD Mn) | 648.5 | 607.4 | 739.4 | 775.3 | 864.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Property investment result (HKD Mn) | -7.1 | -23.0 | -25.0 | -118.3 | -59.8 |
Treasury investment result (HKD Mn) | 2.4 | 3.6 | 5.9 | 2.8 | 0.5 |
Securities investment result (HKD Mn) | 212.7 | -100.8 | 26.0 | -57.8 | -27.2 |
Food businesses result (HKD Mn) | -66.6 | -110.7 | -55.2 | -34.8 | 16.1 |
Healthcare services result (HKD Mn) | -1.9 | -1.8 | -2.7 | -0.5 | 0 |
Property management result (HKD Mn) | — | 9.1 | 9.9 | 9.8 | 9.7 |
Other result (HKD Mn) | -9.1 | -7.8 | -5.1 | 4.3 | -0.8 |
Unallocated corporate expenses (HKD Mn; FY2024 includes litigation settlement) | -123.7 | -99.8 | -95.2 | -505.9 | -72.0 |
Share of associates – Healthway (HKD Mn) | 25.4 | 29.2 | 7.7 | -0.5 | 3.4 |
Share of associates – TIH/other (HKD Mn) | 24.8 | 10.8 | -12.2 | 42.3 | 20.0 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Food segment margin (% of food revenue) | -8.0 | -4.8 | 2.0 |
Food revenue YoY growth (%) | 22.7 | 5.9 | 12.8 |
Food share of group revenue (%) | 92.9 | 93.9 | 95.0 |
Property management margin (% of total segment revenue) | 75.8 | 75.0 | 75.8 |
Property investment total segment revenue incl. inter-segment (HKD Mn) | 22.7 | 21.4 | 21.8 |
Property investment net FV loss on investment properties (HKD Mn) | -25.7 | -37.2 | -20.9 |
Property investment impairment on owner-occupied offices (HKD Mn) | 0 | -79.9 | -40.5 |
Revenue by Segment — Food manufacturing revenue
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Food manufacturing revenue (HKD Mn) | 285.7 | 266.5 | 324.5 | 348.2 | 436.6 |
Restaurant operation revenue (HKD Mn) | 307.4 | 291.1 | 359.9 | 376.1 | 382.7 |
Results by Segment (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Food businesses revenue (HKD Mn) | 392.3 | 411.3 |
Food manufacturing revenue (HKD Mn) | 202.9 | 245.6 |
Restaurant revenue (HKD Mn) | 187.8 | 164.3 |
Food segment result (HKD Mn) | -2.5 | -10.7 |
Property investment result (HKD Mn) | -8.2 | 7.4 |
Securities investment result (HKD Mn) | 5.8 | 8.3 |
Property management result (HKD Mn) | 4.9 | 5.2 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 648.5 | 607.4 | 739.4 | 775.3 | 864.5 |
Cost of sales (HKD Mn) | -316.6 | -290.9 | -309.3 | -300.7 | -332.6 |
Gross profit (HKD Mn) | 332.0 | 316.5 | 430.1 | 474.6 | 531.8 |
Other income – government grants etc. (HKD Mn) | 12.1 | 15.9 | 1.7 | 0 | 0 |
Administrative expenses (HKD Mn) | -392.4 | -379.2 | -399.6 | -409.2 | -436.6 |
Other operating expenses (HKD Mn) | -149.6 | -138.2 | -146.2 | -180.9 | -138.9 |
Operating income, analyst-derived: GP + other income – admin – other opex (HKD Mn) | -197.9 | -185.0 | -114.0 | -115.5 | -43.7 |
Net FV gain/(loss) on FVPL instruments (HKD Mn) | 226.2 | -104.3 | 19.9 | -63.3 | 4.1 |
Net FV loss on investment properties (HKD Mn) | -6.8 | -22.1 | -25.7 | -37.2 | -20.9 |
Impairment of fixed assets, separately presented (HKD Mn) | 0 | 0 | 0 | -79.9 | -40.5 |
Other losses – net (HKD Mn) | -3.1 | -8.0 | -9.8 | -8.7 | -23.3 |
Litigation settlement (HKD Mn) | 0 | 0 | 0 | -386.5 | 0 |
Finance costs (HKD Mn) | -30.2 | -40.0 | -52.3 | -56.7 | -52.6 |
Share of associates (HKD Mn) | 50.2 | 40.0 | -4.5 | 41.8 | 23.4 |
Share of joint ventures (HKD Mn) | -0.4 | -0.4 | 0.3 | -0.5 | 0 |
Profit/(loss) before tax (HKD Mn) | 37.9 | -320.0 | -186.0 | -706.4 | -153.5 |
Income tax credit/(charge) (HKD Mn) | 1.1 | 3.5 | 1.2 | -2.3 | 97.9 |
Profit/(loss) for the year (HKD Mn) | 39.0 | -316.5 | -184.8 | -708.8 | -55.6 |
Attributable to non-controlling interests (HKD Mn) | -9.7 | -38.6 | -38.3 | -25.1 | 5.7 |
Net income attributable to shareholders (HKD Mn) | 48.7 | -277.9 | -146.4 | -683.7 | -61.3 |
Total comprehensive income attributable to shareholders (HKD Mn) | -5.5 | -329.5 | -177.6 | -719.0 | -0.9 |
Depreciation – fixed assets + right-of-use (HKD Mn) | 114.9 | 124.2 | 133.2 | 134.3 | 126.0 |
Adjusted EBITDA, analyst-derived: operating income + D&A (HKD Mn) | -83.0 | -60.8 | 19.2 | 18.8 | 82.3 |
Reported-basis EBITDA, analyst-derived: PBT + finance costs + D&A (HKD Mn) | 183.0 | -155.8 | -0.5 | -515.4 | 25.1 |
Staff costs (HKD Mn) | 315 | 283 | 290 | 297 | 334 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue YoY growth (%) | — | -6.3 | 21.7 | 4.9 | 11.5 |
Gross margin (%) | 51.2 | 52.1 | 58.2 | 61.2 | 61.5 |
Operating margin, analyst-derived (%) | -30.5 | -30.5 | -15.4 | -14.9 | -5.1 |
Adjusted EBITDA margin (%) | -12.8 | -10.0 | 2.6 | 2.4 | 9.5 |
Pre-tax margin (%) | 5.8 | -52.7 | -25.2 | -91.1 | -17.8 |
Net margin attributable (%) | 7.5 | -45.8 | -19.8 | -88.2 | -7.1 |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPS basic and diluted (HKD) | 0.053 | -0.30 | -0.16 | -0.74 | -0.07 |
Dividend per share (HK$, restated) | 0.045 | 0.035 | 0 | 0 | 0 |
Total dividends declared (HKD Mn) | 41.3 | 32.2 | 0 | 0 | 0 |
NAV per share attributable (HKD) | 3.35 | 2.91 | 2.72 | 1.93 | 2.03 |
Weighted average shares (M, restated) | 918.7 | 918.7 | 918.7 | 918.7 | 918.7 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 5,004.7 | 4,392.0 | 3,976.3 | 3,504.0 | 3,464.0 |
Non-current assets (HKD Mn) | 3,530.7 | 3,293.8 | 3,185.2 | 2,945.4 | 2,898.5 |
Current assets (HKD Mn) | 1,474.1 | 1,098.3 | 791.1 | 558.6 | 565.6 |
Cash and cash equivalents (HKD Mn) | 783.3 | 652.8 | 301.6 | 283.2 | 233.9 |
Time deposits >3 months and restricted cash (HKD Mn) | 76.4 | 0 | 0 | 0 | 6.5 |
Fixed assets (HKD Mn) | 1,052.7 | 1,003.2 | 960.5 | 835.3 | 794.6 |
Investment properties (HKD Mn) | 685.7 | 644.4 | 617.1 | 575.5 | 566.9 |
Interests in associates (HKD Mn) | 784.9 | 821.9 | 819.6 | 823.7 | 892.0 |
Interests in joint ventures (HKD Mn) | 75.7 | 76.9 | 78.6 | 78.3 | 41.4 |
Financial assets at FVPL – current + non-current (HKD Mn) | 1,129.4 | 784.6 | 749.3 | 492.9 | 490.1 |
Financial assets at FVOCI (HKD Mn) | 78.5 | 72.6 | 49.3 | 46.3 | 68.1 |
Goodwill and intangibles (HKD Mn) | 21.0 | 21.0 | 21.0 | 21.0 | 21.0 |
Short-term bank and other borrowings (HKD Mn) | 337.1 | 550.9 | 141.8 | 191.6 | 123.7 |
Long-term bank and other borrowings (HKD Mn) | 651.4 | 312.5 | 503.0 | 774.3 | 828.4 |
Total borrowings (HKD Mn) | 988.6 | 863.4 | 644.8 | 965.9 | 952.1 |
Lease liabilities (HKD Mn) | 166.1 | 165.4 | 172.8 | 161.8 | 131.9 |
Net debt excl. leases: borrowings – cash (HKD Mn) | 205.3 | 210.6 | 343.2 | 682.7 | 718.2 |
Total liabilities (HKD Mn) | 1,542.8 | 1,369.0 | 1,151.8 | 1,431.1 | 1,367.8 |
Tax payable (HKD Mn) | 117.4 | 116.5 | 116.8 | 119.2 | 20.6 |
Equity attributable to shareholders (HKD Mn) | 3,078.3 | 2,673.2 | 2,495.8 | 1,776.8 | 1,864.9 |
Non-controlling interests (HKD Mn) | 383.6 | 349.8 | 328.8 | 296.1 | 231.4 |
Total equity (HKD Mn) | 3,462.0 | 3,023.0 | 2,824.5 | 2,072.9 | 2,096.2 |
Working capital – net current assets (HKD Mn) | 731.3 | 179.8 | 291.8 | 29.1 | 118.6 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capital expenditure – segment + unallocated (HKD Mn) | 40.3 | 37.4 | 46.6 | 31.6 | 27.8 |
Dividends paid in cash, analyst-derived from declarations (HKD Mn) | — | 73.5 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | — | 0 | 0 | 0 | 0 |
Adjusted EBITDA minus capex, FCF proxy, analyst-derived (HKD Mn) | -123.3 | -98.2 | -27.4 | -12.8 | 54.5 |
Capital commitments at year-end (HKD Mn) | 114 | 121 | 88 | 84 | 160 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on average attributable equity (%; FY2021 on year-end equity) | 1.6 | -9.7 | -5.7 | -32.0 | -3.4 |
ROA on average total assets (%; FY2021 on year-end assets) | 0.8 | -6.7 | -4.4 | -19.0 | -1.6 |
ROIC: operating income / (total equity + borrowings) (%) | -4.4 | -4.8 | -3.3 | -3.8 | -1.4 |
Current ratio (x) | 1.98 | 1.20 | 1.58 | 1.05 | 1.27 |
Total borrowings / total equity (x) | 0.29 | 0.29 | 0.23 | 0.47 | 0.45 |
Company-defined gearing ratio (%) | 28.4 | 28.6 | 24.8 | 53.0 | 48.1 |
Net debt / adjusted EBITDA (x) | — | — | 17.9 | 36.3 | 8.7 |
Adjusted EBITDA / finance costs (x) | -2.75 | -1.52 | 0.37 | 0.33 | 1.56 |
EBIT (PBT + finance costs) / finance costs (x) | 2.3 | -7.0 | -2.6 | -11.5 | -1.9 |
Asset turnover: revenue / average total assets (x) | 0.13 | 0.13 | 0.18 | 0.21 | 0.25 |
Inventory days | 21.7 | 31.8 | 28.5 | 30.5 | 33.6 |
Trade receivable days | 28.1 | 36.1 | 31.6 | 34.3 | 40.4 |
Trade payable days | 44.8 | 57.3 | 51.9 | 54.3 | 48.2 |
Cash conversion cycle (days) | 5.0 | 10.6 | 8.2 | 10.5 | 25.8 |
Income Statement and Per-Share Data
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Revenue (HKD Mn) | 374.1 | 412.1 | 434.4 |
Gross profit (HKD Mn) | 231.5 | 256.7 | 255.4 |
Administrative expenses (HKD Mn) | -210.6 | -217.0 | -204.8 |
Other operating expenses (HKD Mn) | -94.9 | -75.4 | -79.6 |
Insurance recovery income (HKD Mn) | 0 | 0 | 192.6 |
Finance costs (HKD Mn) | -25.6 | -27.8 | -25.7 |
Profit/(loss) for the period (HKD Mn) | -150.9 | -84.2 | 134.3 |
Profit/(loss) attributable to shareholders (HKD Mn) | -137.3 | -80.3 | 142.1 |
EPS (HKD) | — | -0.09 | 0.15 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong revenue (HKD Mn) | 238.2 | 196.3 | 255.3 | 265.7 | 275.3 |
Mainland China revenue (HKD Mn) | 8.5 | 9.1 | 7.5 | 5.9 | 6.5 |
Singapore revenue (HKD Mn) | 392.0 | 391.6 | 452.9 | 456.6 | 465.9 |
Malaysia revenue (HKD Mn) | 1.0 | 2.5 | 10.5 | 32.8 | 106.8 |
Other revenue (HKD Mn) | 8.9 | 7.8 | 13.2 | 14.4 | 9.9 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong YoY growth (%) | 30.0 | 4.1 | 3.6 |
Mainland China YoY growth (%) | -17.9 | -21.0 | 10.2 |
Singapore YoY growth (%) | 15.6 | 0.8 | 2.0 |
Malaysia YoY growth (%) | 316.4 | 211.4 | 226.1 |
Other YoY growth (%) | 69.9 | 8.5 | -31.2 |
Singapore share of revenue (%) | 61.3 | 58.9 | 53.9 |
Hong Kong share of revenue (%) | 34.5 | 34.3 | 31.8 |
Malaysia share of revenue (%) | 1.4 | 4.2 | 12.4 |
Revenue by Region (FY2023–FY2025)
| Segment × region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Food – Hong Kong (HKD Mn) | 227.5 | 240.7 | 251.2 |
Food – Singapore (HKD Mn) | 447.3 | 452.2 | 462.9 |
Food – Malaysia (HKD Mn) | 9.6 | 31.4 | 105.2 |
Property management – Hong Kong (HKD Mn) | 10.4 | 10.5 | 10.3 |
Property management – Mainland China (HKD Mn) | 2.0 | 1.9 | 2.0 |
Locations
| Location | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong non-current assets (HKD Mn) | 1,118.9 | 974.0 | 870.9 |
Mainland China non-current assets (HKD Mn) | 150.8 | 145.1 | 144.7 |
Singapore non-current assets (HKD Mn) | 948.4 | 946.0 | 999.7 |
Malaysia non-current assets (HKD Mn) | 311.9 | 290.8 | 324.2 |
Other non-current assets (HKD Mn) | 131.3 | 131.8 | 102.5 |
Observation Details
| Observation | Price (HKD) | Market cap (HKD Mn) |
|---|---|---|
~Mar 2025 (FY2024 board-meeting notice) | — | 854.4 |
~Apr 2025 (share-charge release) | — | 808.4 |
~29 May 2025 (trading resumption) | — | 753.3 |
~Sep 2025 (distribution effective) | — | 771.7 |
~Oct 2025 (shareholding update) | — | 836.0 |
Stockopedia (date not stated; 1-year move +21.33%) | 0.91 | 836.0 |
12 Jun 2026 (Google Finance) | 1.02 | 937.1 |
52-week range at 12 Jun 2026 | 0.66 – 1.13 | — |
Valuation Multiples
| Multiple | LCR | Basis |
|---|---|---|
Price / book (attributable NAV) | 0.46x | NAV HK$2,015.5m at 30 Jun 2026 [S4] |
Price / book (FY2025 NAV) | 0.50x | HK$1,864.9m [S1] |
P/E (TTM to Jun 2026) | ~5.8x | TTM profit attributable ≈ HK$161m (FY2025 -61.3 + H1 2026 142.1 – H1 2025 -80.3); includes HK$192.6m one-off insurance income |
EV / Sales (TTM revenue ≈ HK$886.8m) | ~2.0x | EV ≈ HK$1,815m (mkt cap 937 + borrowings 916 + NCI 225 – cash 263), excluding leases |
EV / adjusted EBITDA (TTM ≈ HK$84.5m) | ~23x (lease-inclusive EV ≈ HK$1,935m) | Distorted: EV includes ~HK$2bn of non-EBITDA-generating investments and associates |
Dividend yield | 0% | No dividend since 2022 |
Per-Share Data and Dividends & Capital Returns — Interim DPS
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim DPS (HK cents, pre-consolidation basis) | 0 | 0.35 | 0 | 0 | 0 |
Final DPS (HK cents, pre-consolidation basis) | 0.45 | 0 | 0 | 0 | 0 |
Total dividends declared (HKD Mn) | 41.3 | 32.2 | 0 | 0 | 0 |
Debt Maturity Profile
| Maturity bucket | 31 Dec 2025 (HKD Mn) | 30 Jun 2026 (HKD Mn) |
|---|---|---|
Within one year / on demand | 123.7 (13%) | 137.5 (15%) |
Beyond one year | 828.4 (87%) | 778.5 (85%) |
Total bank and other borrowings | 952.1 | 916.1 |
Analyst Conclusions
Management guidance
There is no quantitative guidance. In the H1 2026 prospects section, management is cautiously optimistic on Hong Kong (2026 GDP forecast raised to 3.5–4.5%) and Singapore (raised to 4.5–5.5%). It expects Mainland growth to slow in H2 2026 and flags materially higher downside risks from the Middle East conflict. The group commits to cautious management of businesses and assets and prudent capital management [S4]. The new production line is expected to be installed in Q4 2026 [S4].
Consensus
Not available. There is one third-party "Hold" with a HK$1.00 target (TipRanks) [S12].
Bull case
-
Manufacturing compounding. Manufacturing revenue grew 25% (FY2025) and 21% (H1 2026). With Q4 2026 capacity added, FY2026–27 group adjusted EBITDA could plausibly exceed the FY2025 level of HK$82m, turning operating income positive for the first time in the period reviewed [S1][S4].
-
Deep value with a catalyst path. At ~0.46x NAV, after the Capital Reduction and with gearing down to 42.1%, the board has both the reserves and the cash (insurance proceeds) to resume dividends. A resumption would re-rate a stock trading below its investment and associate portfolio value alone [S1][S4].
-
Cleaner group structure. The Lippo Limited privatisation and the direct Riady holding through Lippo Capital simplify ownership. The arrival of a 9.30% independent holder (Tai Tak Fung) adds a potential minority voice or catalyst [S11][S12].
Bear case
-
No core profitability. Excluding one-offs, LCR lost money at the operating level in every year from FY2021 to FY2025. Hong Kong retail is deteriorating (-13% in H1 2026), and a HK$437m overhead base consumes most of the gross profit [S1][S4].
-
Volatile, opaque NAV. About half of assets are associates, funds and illiquid holdings. Large historical marks (FY2022 FVPL loss of HK$104m) and impairments (HK$120m on offices, HK$40.7m on a JV) mean book value can erode quickly. Attributable equity fell 39% in four years [S1][S3].
-
Governance and capital-allocation record. The Skye/CS Mining episode cost a net ~US$24.75m after insurance, plus years of legal fees. Related-party funding and interlocking boards keep minority shareholders dependent on the controller's priorities. The holding-company discount may prove permanent [S1][S4].
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | Why it matters |
|---|---|---|
| Commissioning of the new production line | Q4 2026 | Capacity and unit-cost benefits for Malaysian growth |
| FY2026 results and dividend decision | ~Mar 2027 | First full year post-Capital Reduction; dividend resumption test |
| Hong Kong restaurant estate actions | Ongoing | Closures versus refits; segment breakeven |
| Malaysian revenue trajectory and QAF/Gardenia competitive response | Ongoing | Durability of the growth engine |
| Healthway's Bridgepoint acquisition completion | H2 2026 – 2027 | Associate earnings uplift |
| Hong Kong commercial property valuations | Dec 2026 valuation | Revaluation gains or impairment reversals |
| Gearing and related-party loan repayment | Each reporting date | Balance-sheet independence |
| Any corporate action by the Riady group (e.g., privatisation offer) | Unpredictable | Typical exit route for Lippo-group minorities; currently unconfirmed |
| Stephen Tai Tak Fung stake changes | Ongoing | Potential activism or block trade |
Analyst verdict
Lippo China Resources has reached an inflection in balance-sheet terms, but not yet in earnings quality. Since 2024 it has removed its single largest overhang, the Skye/CS Mining litigation, and clawed back half the settlement from insurers. It has also cut gearing from 53% to 42%, reset its share capital to permit distributions, and completed a parent-level restructuring that leaves the Riady family holding about 73% directly and through Skyscraper. At HK$1.02, the shares trade at roughly 0.46x attributable NAV of HK$2.2 per share. Associates, securities and investment properties alone carry about HK$2.06bn, more than twice the market capitalisation.
The operating story is genuinely improving but narrow. Bread manufacturing, especially in Malaysia, is growing more than 20% a year and moved the food segment into profit in FY2025. The Hong Kong café estate, however, is shrinking, and group overhead still absorbs more than 80% of gross profit. Without the HK$104m tax write-back in FY2025 and the HK$193m insurance recovery in H1 2026, the group would have reported losses in both periods. Adjusted EBITDA of about HK$82m does not cover HK$53m of finance costs plus maintenance capex with much room to spare.
The investment case is therefore a NAV-realisation and capital-return thesis rather than a growth compounder. The decisive tests over the next 12 months are threefold: whether the new production line lifts manufacturing margins; whether management uses the newly created distributable reserves to resume dividends; and whether Hong Kong retail can stabilise. Absent a dividend or a controller-led corporate action, the holding-company discount is likely to persist, given low liquidity, no sell-side coverage and a history of value leakage. The rating is Neutral / speculative value. The risk-reward is asymmetric for patient, governance-tolerant investors, but would justify an upgrade only on evidence of recurring profitability or explicit capital returns.
SOURCES REGISTER
S1: LCR Final Results for the year ended 31 Dec 2025 (incl. FY2024 comparatives) — 31 Mar 2026 — https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0331/2026033103919.pdf
S2: LCR Final Results for the year ended 31 Dec 2023 (incl. FY2022 comparatives) — 27 Mar 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0327/2024032702309.pdf
S2b: LCR Date of Board Meeting — 15 Mar 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0315/2024031501343.pdf
S2c: LCR 2023 Annual Report — 29 Apr 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0429/2024042903663.pdf
S3: LCR Final Results for the year ended 31 Dec 2022 (incl. FY2021 comparatives) — 30 Mar 2023 — https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0330/2023033004258.pdf
S4: LCR Interim Results for six months ended 30 Jun 2026 (Chinese version) — 28 Aug 2026 — https://pdf.dfcfw.com/pdf/H2_AN202608281828642708_1.pdf
S5: LCR Positive Profit Alert (H1 2026) — 24 Aug 2026 — https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401119.pdf
S6: LCR Interim Results / Interim Report for six months ended 30 Jun 2025 — 28 Aug 2025 / 29 Sep 2025 — https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0828/2025082801882.pdf ; https://www.hkexnews.hk/listedco/listconews/sehk/2025/0929/2025092901062.pdf
S6b: News brief on H1 2025 interim report (Reuters via Tiger Brokers) — Sep 2025 — https://www.itiger.com/news/2571838300
S6c: LCR Interim Results H1 2024 — 27 Aug 2024 — https://newsfile.moomoo.com/public/NN-PersistNoticeAttachment/7781/20240827/11338240-0.PDF
S7: LCR Retirement of INED and change in board committees — 31 Mar 2026 — https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0331/2026033102533.pdf
S8: LCR Re-designation of ED; appointment of ED and CEO — 6 Jun 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0606/2024060601887.pdf
S9: LCR List of Directors and their roles and functions — 7 Jun 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0607/2024060701020.pdf
S10: LCR Change of INED — 12 Dec 2022 — https://www1.hkexnews.hk/listedco/listconews/sehk/2022/1212/2022121200933.pdf
S11: ET Net company information (major shareholders, bankers, board) — Apr 2026 — https://www.etnet.com.hk/www/eng/stocks/realtime/quote_ci_brief.php?code=156
S12: TipRanks announcement summaries (Lippo privatisation, distribution in specie, shareholding update) — 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-updates-shareholding-structure ; https://www.tipranks.com/news/company-announcements/lippo-limited-announces-privatization-and-delisting-plan
S13: Wikipedia – Lippo Limited (group history) — Accessed Oct 2026 — https://en.wikipedia.org/wiki/Lippo_Limited
S14: Auric Pacific / Délifrance / DKSH / BreadTalk deal sources — 2007–2019 — https://en.wikipedia.org/wiki/D%C3%A9lifrance ; https://www.marktpuls.ch/artikel/permalink/318776 ; https://testing.dev.theedgesingapore.com/capital/ma/breadtalk-buying-over-food-junction-80-mil-auric-pacific ; https://www.hkexnews.hk/listedco/listconews/sehk/2016/0407/LTN201604071281.pdf
S15: Yahoo Finance company profile (key executives, compensation FY2023) — Accessed Oct 2026 — https://nz.finance.yahoo.com/quote/0156.HK/profile
S16: Google Finance / Simply Wall St / Stockopedia quotes — Jun 2026 — https://www.google.com/finance/quote/0156:HKG ; https://simplywall.st/stock/sehk/156 ; https://stockopedia.com/share-prices/lippo-china-resources-HKG:156
S17: Peer filings: QAF Annual Report FY2025; Café de Coral FY2025/26 results; Fairwood FY2025/26 results — Feb–Jun 2026 — https://links.sgx.com/1.0.0/corporate-announcements/S6G3FR58FAT6SQKC/880751_QAF%20Annual%20Report%20FY2025.pdf ; https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0615/2026061500255.pdf ; https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000667.pdf
S18: MarketScreener – King Fai Tsui insider profile (LCR appointment 8 Jun 2026) — Jun 2026 — https://in.marketscreener.com/insider/KING-FAI-TSUI-A07E9W/
S19: News report on FY2025 profit warning (Tiger Brokers) — Mar 2026 — https://www.itiger.com/news/1110788779
S20: LCR Profit Warning FY2023 — 22 Mar 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0322/2024032200911.pdf
S21: LCR 2005 Annual Report (corporate information); 2002 Annual Report — 2006 / 2003 — https://www.hkexnews.hk/listedco/listconews/sehk/2006/0503/0156/EWF103.pdf ; https://www.hkexnews.hk/listedco/listconews/sehk/2003/0506/156/EWF106.pdf
S22: TipRanks summary – proposed Capital Reduction — 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-announces-proposed-capital-reduction-to-address-accumulated-losses
S23: TipRanks summary – release of share charge — Apr 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-announces-release-of-share-charge
S24: TipRanks summaries – FY2024 board meeting; 2025 AGM notice — Mar–May 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-schedules-board-meeting-to-approve-2024-financial-results ; https://www.tipranks.com/news/company-announcements/lippo-china-resources-limited-announces-annual-general-meeting
End of dossier.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Age / born | Prior and concurrent roles |
|---|---|---|---|---|
Dr. Stephen Riady | Executive Director, Chairman | Long-serving; Deputy Chairman, MD and CEO in 2005 | Born 1960 (aggregator) | Chairman of Lippo Limited and Hongkong Chinese Limited; director of Lippo Capital entities; principal of the Riady family interests controlling LCR |
Mr. John Luen Wai Lee, BBS, JP | Executive Director, Deputy Chairman | Director since at least 2002; CEO until 7 Jun 2024, then Deputy Chairman | Aged 75 in Jun 2024 (born 1949) | Formerly MD and CEO of Lippo Limited and CEO of HKC; re-designated Deputy Chairman of Lippo in Jun 2024; Certified Public Accountant |
Mr. Davy Kwok Fai Lee | Executive Director, Chief Executive Officer | Since 7 Jun 2024 (initial two-year term) | Born 1959 (aggregator) | Concurrently ED and CEO of Lippo Limited and HKC from 7 Jun 2024; director and Secretary of Skyscraper Realty; Secretary of Lippo Capital Limited, Lippo Capital Holdings and Lippo Capital Group |
Mr. James Siu Lung Lee | Executive Director | Long-serving | Born 1970 (aggregator) | Described by aggregators as EVP Business Development |
Mr. Brian Riady | Executive Director | — | Born 1990 (aggregator) | — |
Mr. Leon Nim Leung Chan | Non-executive Director | On board since at least 2005 | — | Member of Audit, Remuneration and Nomination Committees |
Mr. Edwin Neo | Independent NED | INED since at least 2005 | — | Chairman of Remuneration and Nomination Committees (2024 list); Audit Committee member |
Ms. Min Yen Goh | Independent NED | Since 30 Dec 2022 | — | Also INED of Lippo Limited and HKC; Remuneration and Nomination Committee member |
Mr. King Fai Tsui | Independent NED; Audit Committee Chairman | Re-appointed 8 Jun 2026 (previously INED Sep 2004 – Dec 2022) | ~76 (aggregator) | INED of Lippo Limited, HKC and Newton Resources; former INED of China Aoyuan and Vinda International |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title |
|---|---|
Mr. Davy Kwok Fai Lee | Chief Executive Officer |
Mr. Shiu Leung Au | Chief Financial Officer (per aggregator; born 1965) |
Ms. Millie Yuen Fun Luk | Company Secretary |
Directors' Remuneration
| Executive | Total remuneration (HKD) | Fiscal year |
|---|---|---|
Dr. Stephen Riady | 12.53m | FY2023 |
Mr. John Luen Wai Lee | 1.99m | FY2023 |
Mr. James Siu Lung Lee | 1.74m | FY2023 |
Mr. Brian Riady | 0.20m | FY2023 |
Mr. Davy Kwok Fai Lee | Not publicly disclosed in retrieved sources | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
30 Dec 2022 | Tsui resigns as INED; Goh appointed INED; Neo becomes Remuneration and Nomination Chair | Board refresh across the Lippo group |
7 Jun 2024 | John Lee moves from CEO to Deputy Chairman; Davy Lee appointed ED and CEO | Coordinated succession across Lippo, HKC and LCR |
31 Mar 2026 | Yung's retirement announced | Personal retirement |
8 Jun 2026 | Yung retires; Tsui re-appointed INED and Audit Committee Chairman | Restores three INEDs, including one with financial expertise |
Major Shareholders
| Holder | Shares | % of issued | Date |
|---|---|---|---|
Skyscraper Realty Limited (Lippo Limited group) | 445,127,921 | 48.45% | 8 Oct 2025 |
Lippo Capital Limited / Stephen Riady & family | 227,427,135 | 24.76% | 8 Oct 2025 |
Mr. Stephen Tai Tak Fung | 85,490,800 | 9.30% | 31 Mar 2026 |
Public float (per company, post-distribution) | — | 26.77% | Sep 2025 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing / ownership | Positioning vs LCR | Revenue (latest verified) |
|---|---|---|---|---|
Packaged bread (SG/MY) | QAF Limited (Gardenia Singapore; 50% JV Gardenia Bakeries KL) | SGX: Q01 | Category leader with far greater scale; announced shifting Gardenia Singapore production to Malaysia | FY2025 revenue S$633.6m (-0.4%) |
Packaged bread (SG/MY) | Gardenia Bakeries (KL) Sdn Bhd | 50% QAF JV | Malaysian market leader | Not separately verified (included in QAF's S$987m proforma revenue) |
Bakery cafés (SG/HK) | BreadTalk Group (incl. Toast Box) | Private (delisted 2020) | Larger multi-brand bakery and café operator | Not publicly disclosed (private) |
Bakery cafés (HK) | Maxim's Caterers (Maxim's Cakes, licensed Starbucks HK) | Private | Dominant HK F&B conglomerate | — |
Bakery cafés (HK) | Saint Honoré Cake Shop | Private | HK bakery chain | — |
Casual dining / QSR (HK) | Café de Coral Holdings | HKEX: 0341 | Largest listed HK fast-food group | FY2025/26 (Mar-26) revenue HK$8,183.1m (-4.5%); profit HK$164.1m |
Casual dining / QSR (HK) | Fairwood Holdings | HKEX: 0052 | HK fast-food peer | FY2025/26 (Mar-26) revenue HK$3,098.8m (flat); profit HK$41.6m |
Casual dining (HK) | Tai Hing Group | HKEX: 6811 | Cha chaan teng / roast-meat chain | — |
Café chains (HK) | Pacific Coffee | Private (China Resources group) | Café competitor | — |
Primary healthcare (SG; associate) | Raffles Medical Group, Parkway Shenton (IHH), OneCare, Fullerton Health | Various | Healthway competes in GP and specialist care | — |
PE / fund management (associate) | Southeast Asian mid-market PE managers | Various | TIH is small-cap | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | LCR (FY2025, Dec) | Café de Coral (FY2025/26, Mar) | Fairwood (FY2025/26, Mar) | QAF (FY2025, Dec) |
|---|---|---|---|---|
Revenue | HK$864.5m | HK$8,183.1m | HK$3,098.8m | S$633.6m |
Revenue growth | +11.5% | -4.5% | ~0% | -0.4% |
Gross margin | 61.5% (cost of sales excludes labour and rent) | 9.5% | 8.7% | — |
Adjusted EBITDA margin | 9.5% (analyst-derived) | 7.0% (HK$572.6m) | — | — |
Net margin (attributable) | -7.1% | 2.0% | 1.3% | — |
R&D intensity | Not disclosed (nil) | — | — | — |
Dividend | Nil | HK$0.40/share (FY total) | — | S$0.04 final (per AR) |
“—” = not publicly disclosed.
Recent Developments
--



